ALLIANCE FOR REGENERATIVE MEDICINE
JA
The past 12 months
Clients
1
past 12 months
Filings
1
past 12 months
Agencies contacted
Centers For Medicare and Medicaid Services (CMS)Food & Drug Administration (FDA)HOUSE OF REPRESENTATIVESHealth & Human Services, Dept of (HHS)Natl Institutes of Health (NIH)SENATE
Specific issues
Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.
Clients
Sources
This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗
Recent filings1
lda.gov →